Core Insights - The company faced revenue pressure but significantly improved profitability, with a 2024 revenue of 4.001 billion yuan (down 2.98% year-on-year) and a net profit of 397 million yuan (down 29.46% year-on-year) [1] - The company reported a gross margin of 57.49% for 2024, an increase of 4.61 percentage points, attributed to a higher proportion of high-margin formulations and optimized raw material costs [1] Revenue Breakdown - In 2024, the formulation sales revenue was 2.415 billion yuan (up 6.02% year-on-year), with significant growth in anesthetic muscle relaxants (up 55%) and respiratory products (up 31%), while generic drug formulation revenue decreased by 19% [2] - Raw material and intermediate revenue fell to 1.547 billion yuan (down 13.4% year-on-year), primarily due to intensified competition and price declines in the non-standard market [2] Growth Potential - The company has a strong pipeline with four new generic drug approvals in 2024, including the first domestic generic version of estradiol valerate tablets [3] - The company is expanding internationally, with raw materials like medroxyprogesterone acetate receiving WHO PQ certification and prednisone receiving PMDA certification in Japan [3] - Earnings per share forecasts for 2025-2027 have been adjusted to 0.69, 0.80, and 0.97 yuan, respectively, with a target price of 11.04 yuan based on a 16x P/E ratio for 2025 [3]

Investment Rating - Industry Rating: Outperform the Market (maintained rating) [4] Core Insights - The pharmaceutical raw material sector showed a preliminary trend of marginal stabilization and recovery in Q1 2025, with key characteristics including the stabilization of raw material prices, integration of formulations, and the transition to new business models [1][2][3] Summary by Sections Raw Material Prices - After a year of continuous price decline in 2024, some raw material prices in Q1 2025 have shown signs of stabilization, with year-on-year declines but month-on-month increases for certain products. Companies have indicated that products with significant price drops in 2024 are stabilizing or increasing in price in 2025. The overall theme for 2024 was to exchange price for volume, while 2025 is expected to enter a phase of stable prices and increased volume [1] Formulation Integration - Companies like Tianyu Co. have experienced growth in Q1, partly due to the expansion of formulation product lines and the renewal of national procurement contracts. For companies with annual revenue below a certain threshold (e.g., 500 million), the rapid growth of formulation business is expected to significantly contribute to profits within the next 2-3 years [2] New Business Transition - Traditional raw material business margins have been shrinking due to intense competition. Therefore, expanding into innovative businesses is essential for the transformation of raw material companies. Companies are beginning to see returns from new business ventures, such as innovative drugs and complex formulations, with examples including Huahai Pharmaceutical's new monoclonal antibodies and Aorite's small nucleic acid technology platform [3]

Core Viewpoint - Xianju Pharmaceutical is facing an administrative penalty of approximately 200 million yuan for allegedly engaging in a monopoly agreement related to the pricing of Dexamethasone Sodium Phosphate raw materials, as disclosed in its annual report [1][6]. Group 1: Administrative Penalty Details - The Tianjin Municipal Market Supervision Administration has issued a notice indicating that Xianju Pharmaceutical is suspected of reaching and implementing a monopoly agreement by fixing and changing the price of Dexamethasone Sodium Phosphate raw materials [1][6]. - The proposed administrative penalty includes the confiscation of illegal gains amounting to 23.75 million yuan and a fine of 172 million yuan, which is 8% of the company's sales in 2023, totaling approximately 195 million yuan [6]. - Xianju Pharmaceutical has acknowledged the expected liabilities and related losses in its financial statements for 2024, in accordance with the administrative penalty notice [6]. Group 2: Market Context and Impact - Dexamethasone Sodium Phosphate is widely used in clinical treatments for allergic and autoimmune inflammatory diseases, with sales in Chinese public medical institutions reaching nearly 1.2 billion yuan in 2023, reflecting a year-on-year growth of 59.27% [6]. - The sales figure for Dexamethasone Sodium Phosphate was less than 400 million yuan in 2021, indicating significant growth in demand [6]. - Xianju Pharmaceutical's total revenue for 2024 is reported at 4 billion yuan, a decrease of 2.98% year-on-year, with net profit declining by 29.46% to 397 million yuan, attributed partly to the impact of national centralized drug procurement on its products, including Dexamethasone Sodium Phosphate [8]. Group 3: Regulatory Environment - The case is currently in the administrative penalty notification stage, and the Tianjin Municipal Market Supervision Administration has stated that the details will be publicly disclosed after the case is processed [10]. - Previous cases of pharmaceutical companies facing penalties for monopolistic practices highlight a growing regulatory scrutiny in the industry, with significant fines imposed on companies for similar violations [9].

证券代码：002332 证券简称：仙琚制药 浙江仙琚制药股份有限公司 投资者关系活动记录表 编号：2025 -02 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2024年度网上业绩说明会的全体投资者 | | 时间 | 2025年04月28日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 张宇松 | | | 总经理 金炜华 | | 上市公司接待人员姓名 | 财务总监 王瑶华 | | | 副总经理、董事会秘书 张王伟 | | | 独立董事 张红英 1.公司股价逆大盘下跌，是什么原因 | | | 答:您好！股价波动受行业政策、市场风格、公司发展阶段等 | | 投资者关系活动主要内容 | 多种因素影响。公司专注做好主业，持续提高运营效率和管理水 | | 介绍 | 平，促进公司长期稳健可持续发展，努力 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 11.04 CNY based on a 16x P/E ratio for 2025 [2][5]. Core Views - The company's revenue is under short-term pressure, but there is sufficient growth momentum. The revenue forecast for 2025-2027 has been adjusted, with expected earnings per share of 0.69 CNY, 0.80 CNY, and 0.97 CNY respectively [2][8]. - The company achieved a revenue of 4.001 billion CNY in 2024, a decrease of 3.0% year-on-year, and a net profit attributable to the parent company of 397 million CNY, down 29.5% year-on-year. However, the gross margin improved to 57.5% due to a higher proportion of high-margin formulations [4][8]. - The company has a clear growth trajectory with new product approvals and ongoing international expansion efforts. In 2024, four generic drug projects were approved, and several others are in various stages of development [8]. Financial Summary - **Revenue Forecast**: - 2023: 4,123 million CNY - 2024: 4,001 million CNY - 2025: 4,598 million CNY (14.9% growth) - 2026: 5,361 million CNY (16.6% growth) - 2027: 6,336 million CNY (18.2% growth) [4][10] - **Net Profit**: - 2023: 563 million CNY - 2024: 397 million CNY - 2025: 683 million CNY (71.9% growth) - 2026: 796 million CNY (16.5% growth) - 2027: 961 million CNY (20.8% growth) [4][10] - **Earnings Per Share**: - 2023: 0.57 CNY - 2024: 0.40 CNY - 2025: 0.69 CNY - 2026: 0.80 CNY - 2027: 0.97 CNY [4][10] - **Profitability Ratios**: - Gross Margin: 52.9% (2023), 57.5% (2024), 57.0% (2025E), 57.8% (2026E), 58.0% (2027E) - Net Margin: 13.7% (2023), 9.9% (2024), 14.9% (2025E), 14.8% (2026E), 15.2% (2027E) [4][10]

Investment Rating - The report maintains a "Recommended" rating for the company [6][8]. Core Views - The company experienced a decline in revenue and net profit in 2024, with total revenue of 4.0 billion yuan, down 3.0% year-on-year, and a net profit of 0.4 billion yuan, down 29.5% year-on-year. However, the adjusted net profit increased by 2.2% year-on-year to 0.55 billion yuan [3]. - The company's formulation business showed steady growth, with revenue of 2.42 billion yuan, up 6.0% year-on-year, while the raw material drug segment faced a decline in revenue of 1.55 billion yuan, down 13.4% year-on-year [4]. - The report highlights the potential for growth in the company's unique and innovative products, which are expected to drive the formulation business to new heights [5]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 4.0 billion yuan, with a net profit of 0.4 billion yuan. The first quarter of 2025 saw revenue of 1.01 billion yuan, down 2.9% year-on-year, and a net profit of 0.14 billion yuan, down 4.7% year-on-year [3]. - The company forecasts a recovery in net profit from 0.64 billion yuan in 2025 to 0.77 billion yuan in 2027, with corresponding growth rates of 61.2%, 7.0%, and 11.7% [6][7]. Business Segments - The formulation business is the main growth driver, with significant contributions from respiratory and dermatological products, while the raw material drug segment is under pressure due to price declines [4][5]. - The report notes that the company is focusing on upgrading its product offerings and increasing its share in high-end markets, which is expected to stabilize the raw material drug business in the long term [6]. Future Outlook - The company is expected to benefit from the launch of innovative products and the growth of unique products, which will likely enhance its market position and drive revenue growth [5][6].

Regulatory Developments - The National Health Commission and other departments have released the 2025 National Random Supervision and Inspection Plan, which includes new regulatory areas such as internet diagnosis and treatment, and mental health, while explicitly targeting online medical fraud [1] - The regulatory focus on combating online medical fraud represents a significant upgrade in medical supervision, aiming to purify the medical online space [1] Pharmaceutical Approvals - Innovent Biologics announced that its third-generation EGFR TKI drug, Olitinib (Leratinib), has received approval from the National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [2] - Olitinib is the only approved third-generation EGFR TKI based on a naphthalene structure, expanding treatment options for EGFR mutation-positive NSCLC patients [2] Market Regulation and Antitrust Issues - Xianju Pharmaceutical is facing a potential fine of approximately 195 million yuan for alleged monopolistic practices related to the pricing of dexamethasone phosphate raw materials, with the case still under review by the Tianjin Market Supervision Administration [3] - This incident highlights the regulatory authorities' emphasis on antitrust measures within the pharmaceutical industry, which could disrupt normal market operations [3] Combination Therapy Approvals - Pfizer announced that its oral targeted drug, Axi-cabtagene ciloleucel (Axitinib), has been approved for first-line treatment in combination with Toripalimab for high-risk, unresectable, or metastatic renal cell carcinoma (RCC) patients [4] - This approval marks the first and only approved first-line targeted and immune combination therapy for advanced kidney cancer in China, indicating a shift towards combination therapies in the treatment landscape [4]

一纸天价罚单再次揭开医药行业价格操纵的冰山一角。4月23日，仙琚制药（002332.SZ）在年报中披 露，因涉嫌地塞米松磷酸钠原料药价格垄断，公司拟被天津市市场监管委员会罚没1.95亿元。这场涉及 临床常用药的"价格过山车"事件，暴露出集采时代原料药市场的监管风暴正在升级。 垄断罚单直击核心产品 集采落标加速行业洗牌 第九批国家集采中，地塞米松磷酸钠注射液最低中标价2.3元/盒，而仙琚制药未能入围。随着集采常态 化，公司年报坦承包括该产品在内的多款制剂销售收入持续下滑。目前该原料药市场已形成7家持证企 业的竞争格局，集采机制正在重塑行业利润分配模式。 监管利剑高悬 责任编辑：AI观察员 本次处罚是继2023年国家市场监管总局通报哄抬药价案后的又一记重拳。值得关注的是，处罚依据首次 采用"销售额比例罚则"，相较于国药黔东南70万元罚款，监管力度显著升级。业内分析认为，在医保控 费主基调下，原料药领域反垄断执法将成常态，拥有市场支配地位的企业面临更高合规成本。 面对1.95亿罚单和集采双重压力，仙琚制药在年报中明确将调整产品结构。但这场风波揭示的深层问题 ——如何在保障药品可及性与维持企业合理利润间找到平衡，仍将 ...

仙琚制药 20250424 摘要 • 2024 年仙琚制药营收 40 亿元，同比下降 2.86%，归母净利润 3.97 亿元， 同比下降 29%，主要受集采、原料降价及国际需求疲软影响。扣非净利润 5.49 亿元，实现正增长。2025 年一季度净利润 1.44 亿元，同比下降 2.86%，剔除出售子公司股权收益影响后基本持平。 • 公司制剂业务收入 24.15 亿元，同比增长 6%，其中妇科药品收入基本持 平，麻醉肌松剂增长 55%，呼吸科药品增长 31%，皮肤科药品增长 19%，普药类产品下降 20%。黄体酮胶囊销售额同比下降 6%，左炔诺孕 酮胶囊下降 23%。 • 麻醉肌松剂业务集采后恢复性增长，罗库溴铵收入同比翻番，顺阿曲库铵 增长 37%，舒更葡糖钠大幅增长。呼吸科药品康喷销售额同比增长 40%，赛托溴胺略有下滑。皮肤科药品主要增长来自康酸乳膏和丙酸氟替 卡松乳膏。 • 普药类产品受集采及库存整理影响下滑，预计二三季度逐步恢复，但难以 恢复至 2023 年水平。公司计划将普药升级为无菌产品，实现技术升级换 代。一季度非规市场原料药价格持续下降，但跌幅较去年有所减缓。 Q&A 请介绍一下 2024 年 ...

证券代码：002332 证券简称：仙琚制药 浙江仙琚制药股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | 特定对象调研 | | 现场会议□分析师会议 | | | | | --- | --- | --- | --- | --- | --- | --- | | 类别 | 媒体采访 | | □业绩说明会 | | | | | | □新闻发布会 | | □路演活动 | | | | | | □现场参观 | | 其他  | 电话会议 | | | | 参 与 单 位 名 称 | 祝嘉琪 | 中泰证券 | 赵辉 | 博时基金 | 蒯学章 | 大家资管 | | | 何玮 | 东方财富 | 朱述政 | 光大理财 | 田鑫 | 广发医药 | | 及人员姓名 | 吴晗 | 国君医药 | 文惠霞 | 国都证券 | 潘天奇 | 国联基金 | | | 刘柏川 | 国联基金 | 浩 陈 | 国联基金 | 李博闻 | 国寿安保 | | | 浩 陈 | 国联基金 | 李博闻 | 国寿安保 | 周航 | 国泰海通 | | | 唐巍 | 荷荷(北京) | 陆元娅 | 红土创新 | 张丽青 | 鸿运私募 | | | ...